City

Clinical trials near Ostrava, Czechia

Active studies with a listed research site in Ostrava, Czechia.

16active studies

5recruiting now

17countries represented

188largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowNot applicable

Small Bowel Diversion

Obesity, Type2 DiabetesCondition

jejuno-ileal diversion, jejuno-colic diversionTreatment

Czechia2 locations

University of OstravaSponsor

Updated 2025-08-19 · NCT06374368See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Active, not recruitingPhase 3

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Obesity, Overweight and/or ObesityCondition

PF-08653944, PlaceboTreatment

Argentina, Bulgaria188 locations

PfizerSponsor

Updated 2026-09-08 · NCT07400653See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Obesity and OverweightCondition

MET097, PlaceboTreatment

Bulgaria, Canada169 locations

PfizerSponsor

Updated 2026-09-04 · NCT07311850See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Ostrava, Czechia

Current studies

Related cities